Company Overview and News
Legg Mason Inc.’s (LM - Free Report) chief executive officer (CEO) Joseph A. Sullivan’s total compensation, including a cash bonus, had been increased to $9.7 million in fiscal 2018. This represents a jump of 8% from the prior fiscal on higher incentives, according to a regulatory filing of Jun 20. In fiscal 2018, Sullivan’s pay package included salary of $500,000, unchanged from fiscal 2017, a cash bonus of $4 million (up from $3.
LAZ LMHA PBB LMHB LM AB PSEC
Here's your June 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains reports. Nano-Cap MoPays are not listed.
SCA CCAOF "NHF" CJ CBL WSR CRLFF AD ALARF CRIUF ORC MHIVF OXLCO OXLCN SCM ATGFF SOT.UN CJR.B ECC AMZA ECCZ AGNC AHOTF ECCY PHK SRRTF QYLD PSEC OXLC ECCB NCV CJREF SCQ ECCA SUNS GNL NCZ NHF GNL.PRA PBB SRT.UN
Two of PSEC's largest investments will likely have upcoming writedowns, especially given that company has a fiscal year-end June 30, requiring a full audit.
CLA MCQ TCAP KAP PNNT MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA MCC ARCC HCAPL GBDC FDUS MAIN TCC TCPC PSEC HTGX NMFC HTGY OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PBB PNTA
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ:PSEC) (“Prospect”, “our”, or “we”) announced today the pricing of $70 million in aggregate principal amount of senior unsecured 5.875% Senior Notes due 2023 (the “Notes”).
PBB BR PSEC
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ:PSEC) (“Prospect”, “our”, or “we”) today announced it has been assigned an investment grade credit rating of BBB from Egan-Jones Ratings Company (“Egan-Jones”).
Part 2 of this article discusses two topics/trends impacting PSEC’s future dividend and NAV sustainability (forward-looking metrics).
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSI MSCA.CL OCSL MCX TRI NEWTL PBB
Following continued requests from readers, this article first performs a FMV investing rating analysis on TSLX’s portfolio companies over the prior four quarters.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX JIVE NEWTL PBB
For those looking to find strong Finance stocks, it is prudent to search for companies in the group that are outperforming their peers. Prospect Capital (PSEC - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of PSEC and the rest of the Finance group's stocks.
This article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX NEWTL PBB
Following multiple requests by readers, this article analyzes TSLX’s dividend sustainability by performing three tests based on historical and projected future quarterly results.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC FSIC MAIN AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX NEWTL PBB
Invesco Ltd. (IVZ - Free Report) recently announced that it has acquired the leading U.K.-based advisor-focused digital solutions firm, Intelliflo from HG Capital Trust. The financial terms of the deal, not expected to have any material impact on the company’s earnings, were kept under wraps. Invesco’s plan to resume share repurchase by this year-end, following the reduction in its debt leverage, will not be impacted by this acquisition.
HGT LAZ NOAH PBB PSEC IVZ
Following continued requests, Part 1 of this article analyzes PSEC’s near-term dividend sustainability by performing three tests based on recent (and projected) quarterly results.
MSCA.CL SLRC MSCA MAIN PBB SLRA PSEC
NEW YORK, June 04, 2018 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ:PSEC) (“Prospect”) announced today that Prospect has purchased $75 million of first lien senior secured floating rate notes and $5 million of revolving credit issued to support the acquisition of Eze Castle Integration, LLC (“ECI”) by affiliates of H.I.G. Capital, LLC (“H.I.G.”).
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET